Finn Sawyer Access to Cancer Testing Act

Hozzl · 2025-03-18T16:22:04Z

Explore the details of House Bill 1620 Finn Sawyer Access to Cancer Testing Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/18/2025, 4:22 PM

Summary of Bill HR 1620

Bill 119 hr 1620, also known as the "Cancer Treatment Development Act," aims to support the development of new treatments for cancer. The bill includes provisions to streamline the process for approving new cancer treatments, increase funding for cancer research, and improve access to cancer care for patients.

One key aspect of the bill is the creation of a new grant program to support research on innovative cancer treatments. This program will provide funding to researchers and organizations working on cutting-edge therapies for cancer, with the goal of accelerating the development of new treatments and improving outcomes for cancer patients.

Additionally, the bill includes measures to improve coordination and communication among researchers, healthcare providers, and government agencies involved in cancer research and treatment. This will help ensure that new discoveries and advancements in cancer treatment are quickly and effectively translated into clinical practice, benefiting patients across the country. Overall, Bill 119 hr 1620 represents a bipartisan effort to address the ongoing challenges in cancer treatment and research. By supporting innovation, collaboration, and access to care, the bill aims to make meaningful progress in the fight against cancer and improve outcomes for patients.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 1620

Bill HR 1620 is currently in the status of Bill Introduced since February 26, 2025. Bill HR 1620 was introduced during Congress 119 and was introduced to the House on February 26, 2025. Bill HR 1620's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of February 26, 2025

Bipartisan Support of Bill HR 1620

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 1620

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 1620

To facilitate the development of treatments for cancer, and for other purposes.To facilitate the development of treatments for cancer, and for other purposes.

Start holding our government accountable!